Earlier this week, Daiichi Sankyo and AstraZeneca received approval in China for ENHERTU as the first HER2-directed ...

A U.S. appeals court on Friday reinstated a lawsuit claiming some of the world’s largest drug and medical‑device companies ...

LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens ...

GSK is set to buy Rapt Therapeutics in a $2.2 billion deal. AstraZeneca agreed to a $630 million pact to secure remaining rights to armored CAR-T from AbelZeta. Bristol Myers Squibb signed a deal with ...

AstraZeneca Canada is pleased to announce that Tagrisso® (osimertinib) and Calquence® (acalabrutinib tablets) are now publicly funded in Ontario and are among the first therapies to receive ...

The UK government is under increasing pressure on Monday to review its COVID-19 vaccine protocol in place for travellers from India, after its updated rules effective from next month failed to ...

British finance minister Rachel Reeves will accompany Prime Minister Keir Starmer on his trip to China next week, ...

Japanese pharma Daiichi Sankyo (TSE: 4568) and British partner AstraZeneca (LSE: AZN) said Enhertu (trastuzumab deruxtecan) ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Daiichi Sankyo and AstraZeneca’s Enhertu has received approval from China’s NMPA for adult patients with locally advanced or ...

Daiichi Sankyo & AstraZeneca’s Enhertu approved in China as first and only HER2 directed ADC for second-line treatment of patients with HER2 positive metastatic gastric cancer ...